echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Zynlonta has significant efficacy in the treatment of malignant lymphoma and has been approved for clinical trials in China

    Zynlonta has significant efficacy in the treatment of malignant lymphoma and has been approved for clinical trials in China

    • Last Update: 2021-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Swiss biotech company ADC Therapeutics SA recently announced new data from two clinical trials of CD19 targeted antibody conjugate (ADC) Zynlonta (loncastuximab tesirine-lpyl) at the 16th International Annual Conference on Malignant Lymphoma (ICML)


    The latest results from the LOTIS-2 trial demonstrate Zynlonta’s long-lasting response in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have been heavily-preteated (previously received multiple therapies) The median duration of response (DOR) reached 13.


    Zynlonta is an antibody-conjugated drug (ADC) targeting CD19.


    Molecular structure of loncastuximab tesirine

    In April 2021, Zynlonta received accelerated approval from the US FDA for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) who have received 2 or more systemic therapies, including diffuse Large B-cell lymphoma (DLBCL), DLBCL originating from low-grade lymphoma and high-grade cell lymphoma


    In China, Zynlonta is being developed by Overland ADCT BioPharma, a joint venture established by ADC Therapeutics and Overland Pharmaceuticals


    It is worth mentioning that Zynlonta is the first and only CD19-targeted ADC as a single agent to treat adult patients with r/r DLBCL


    Zynlonta mechanism of action

    LOTIS-2 trial follow-up analysis data:

    LOTIS-2 is a single-arm, open-label clinical trial (n=145), carried out in patients with relapsed or refractory DLBCL who have previously received at least 2 systemic therapies and failed to evaluate the efficacy and efficacy of Zynlonta monotherapy.


    The latest results released this time show that Zynlonta monotherapy shows sustained anti-tumor activity and acceptable safety


    LOTIS-3 trial follow-up analysis data:

    LOTIS-3 trial follow-up analysis data:

    LOTIS-3 is a phase 1/2, two-part, open-label, one-arm clinical trial that is evaluating the efficacy of Zynlonta combined with ibrutinib (ibrutinib, BTK inhibitor) in the treatment of relapsed or refractory DLBCL or MCL


    Key data include: ORR of 62.


    Original source: ADC Therapeutics Presents Updated ZYNLONTA (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma

    This article is from Bio Valley, for more information, please download the Bio Valley APP (http://

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.